Smaller trials for better evidence

The interesting debate between Parker and Anderson & Haddad ([2003][1]) suggests more fundamental reasons to question prevailing research paradigms and designs in respect of the efficacy of and indications for psychotropic medicines. That the clinical trial industry reveals even marginal drug